“However, recent studies have shown that the glucocorticoid receptor also has an oncogenic, or cancer-promoting, effect in cancers like breast and prostate cancer. In prostate cancer, the glucocorticoid receptor can replace the activity of the androgen receptor, which is main oncogenic factor in this cancer, when its activity is inhibited by drug therapy. Thus, glucocorticoids help prostate cancer develop resistance to drug therapy.”
University of Eastern Finland. "New insight into combating drug-resistant prostate cancer." ScienceDaily. ScienceDaily, 10 April 2024 sciencedaily.com/releases/2...
Journal References:
Jasmin Huttunen, Niina Aaltonen, Laura Helminen, Kirsi Rilla, Ville Paakinaho. EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells. Cellular and Molecular Life Sciences, 2024; 81 (1) DOI: 10.1007/s00018-024-05209-z
Laura Helminen, Jasmin Huttunen, Melina Tulonen, Niina Aaltonen, Einari A Niskanen, Jorma J Palvimo, Ville Paakinaho. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer. Nucleic Acids Research, 2024; 52 (2): 625 DOI: 10.1093/nar/gkad1126